Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SZKXH
ADC Name
BYON-3521
Synonyms
BYON 3521; BYON-3521; BYON3521
   Click to Show/Hide
Organization
Syntarga BV; Byondis BV
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Undisclosed
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
seco-DUBA
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Reactive Cysteines
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05323045
Phase 1
A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with previously treated progressive locally advanced or metastatic solid tumors, MET positive.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT05323045  Clinical Status Phase 1
Clinical Description A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.
References
Ref 1 A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer NCT05261269. Cancer Res (2023) 83 (5_Supplement): OT3-28-01.